Neel Mehta
CSRA‘s (NYSE: CSRA) DynPort Vaccine subsidiary has been awarded a spot on a potential 10-year, $159 million contract to handle various medical product development initiatives for the National Institute of Allergy and Infectious Diseases.
DynPort will work to create manufacturing processes and analytical test methods, characterize and manufacture products and provide regulatory support for the development of infectious disease therapies, CSRA said Tuesday.
DynPort is one of four awardees of the indefinite-delivery/indefinite-quantity contract, with funding from NIAID, the National Institutes of Health and the Department of Health and Human Services.
“NIAID has been at the forefront of implementing new therapies, vaccines, diagnostic tests and other technologies that have improved the lives of millions of people around the world and we are honored to support their efforts,” said Gary Nabors, president of DynPort Vaccine.
NIH’s NIAID works to treat and prevent infectious, immunologic and allergic diseases.
